Table 3.

Subgroup analyses of overall survival between the high and low score groups.

		Cohorts, n	Patients, n	HR (95%CI)	p value	I2 (%)
Country	Total	19	4625	2.07(1.73–2.48)	<0.0001	62
	Asian	11	3050	1.76(1.45–2.13)	<0.0001	29
	Non-Asian	8	1575	2.54(1.94–3.34)	<0.0001	62
Study design	Prospective	2	376	5.98(3.11–11.51)	<0.0001	0
	Retrospective	17	4249	1.95(1.64–2.30)	0.002	56
Study center	Single center	16	4169	2.09(1.73–2.54)	<0.0001	64
	Multicenter	3	456	1.99(1.05–3.78)	0.03	63
Sample size	>150	8	3478	2.23(1.71–2.90)	<0.0001	71
	≤150	11	1147	1.94(1.49–2.52)	<0.0001	55
Cancer type	Gastrointestinal	7	2750	2.01(1.49–2.73)	<0.0001	70
	Lung	8	1236	1.68(1.34–2.11)	<0.0001	25
	Mixed	4	639	2.98(2.32–3.81)	<0.0001	13
Primary treatment	Surgery	3	2122	1.86(1.38–2.50)	<0.0001	0
	ICI	9	1134	2.27(1.68–3.07)	<0.0001	71
	CT	5	778	1.74(1.16–2.61)	0.007	67
	Others	2	591	2.53(1.99–3.22)	<0.0001	0
TNM stage	Non-metastatic	2	543	2.37(1.45–3.88)	0.006	0
	Metastatic	6	930	2.67(2.06–3.46)	<0.0001	40
	Mixed	11	3152	1.76(1.42–2.19)	<0.0001	59
Analysis method	Univariate	9	1040	2.30(1.75–3.01)	<0.0001	56
	Multivariate	10	3585	1.90(1.49–2.42)	<0.0001	65